Brief: Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
22/05/2025 13:38
May 22 (Reuters) - Evaxion A/S EVAX.O: EVAXION DOSES FIRST PATIENT IN EXTENSION OF PHASE 2 TRIAL EXPLORING THE FULL POTENTIAL OF AI-DESIGNED PERSONALIZED CANCER VACCINE EVX-01 EVAXION A/S - TRIAL ON TRACK FOR TWO-YEAR DATA READOUT IN H2 2025 Source text: ID:nGNX1lvH1W Further company coverage: EVAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evaxion A/S
See all newsEvaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Denmark's Evaxion Q2 net loss narrows on lower expenses
Brief: Evaxion Q2 Basic EPS USD -0.01
Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Brief: Evaxion A/S - Expands Pipeline Of Cancer Vaccine Programs With Evx-05 Against Brain Cancer Glioblastoma